Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials

European Neuropsychopharmacology

Volumn 23, Issue 9, 2013, Pages 1023-1033

  Dold, Markus ^a   Li, Chunbo ^b   Gillies, Donna ^c   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CUMBERLAND HOSPITAL   (Australia)

Author keywords

Antipsychotics; Augmentation treatment; Benzodiazepines; Meta analysis; Schizophrenia

Indexed keywords

BENZODIAZEPINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLONAZEPAM; DIAZEPAM; ESTAZOLAM; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; PLACEBO; THIORIDAZINE;

ADD ON THERAPY; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CHRONIC DISEASE; DEMENTIA; DEPRESSIVE PSYCHOSIS; DIZZINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC PSYCHOSIS; HEBEPHRENIA; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; NEGATIVE SYNDROME; NEUROSIS; PARANOIA; PARANOID PSYCHOSIS; PARANOID SCHIZOPHRENIA; PHOBIC NEUROSIS; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; RESIDUAL SCHIZOPHRENIA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIMPLE SCHIZOPHRENIA; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNDIFFERENTIATED SCHIZOPHRENIA; UNSPECIFIED SCHIZOPHRENIA;

ANTIPSYCHOTICS; AUGMENTATION TREATMENT; BENZODIAZEPINES; META-ANALYSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84884202943     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.03.001     Document Type: Article

References (49)

1. Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.J., WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive, and post-traumatic stress disorders, 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry 9, 2248-2312.
2. Barbee J., Mancuso D., Freed C., Todorov A.A. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am. J. Psychiatry 1992, 149:506-510.
3. Battaglia J., Moss S., Rush J., Kang J., Mendoza R., Leedom L., Dubin W., Mc Glynn C., Goodmann L. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am. J. Emerg. Med. 1997, 15:335-340.
4. Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H. Comprehensive Meta-Analysis, Version 2 2006, Biostat, Englewood, New York.
5. Cheine M., Ahonen J., Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database Syst. Rev. 2001, CD000234.
6. Christison G.W., Kirch D.G., Wyatt R.J. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr. Bull. 1991, 17:217-245.
7. Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?. Expert. Rev. Neurother 2009, 9:55-71.
8. Correll C.U., Shaikh L., Gallego J.A., Nachbar J., Olshanskiy V., Kishimoto T., Kane J.M. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviour. Schizophr. Res. 2011, 131:58-62.
9. Der-Simonian R., Laird N. Meta-analysis in clinical trials. Control Clin. Trials 1986, 7:177-188.
10. Dold, M., Li, C., Tardy, M., Khorsand, V., Gillies, D., Leucht, S., 2012. Benzodiazepines for schizophrenia. Cochrane Database Syst. Rev. CD006391.
11. Dorevitch A., Katz N., Zemishlany Z., Aizenberg D., Weizman A. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am. J. Psychiatry 1999, 156:142-144.
12. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 1997, 315:629-634.
13. Gallego J.A., Bonetti J., Zhang J., Kane J.M., Correll C.U. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr. Res. 2012, 138:18-28.
14. Garza-Trevino E.S., Hollister L.E., Overall J.E., Alexander W.F. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am. J. Psychiatry 1989, 146:1598-1601.
15. Gillies, D., Beck, A., McCloud, A., Rathbone, J., Gillies, D., 2005. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst. Rev. CD003079.
16. Guz I., Moraes R., Sartoretto J.N. The therapeutic effects of lorazepam in psychotic patients treated with haloperidol - a double blind study. Curr. Ther. Res. Clin. Exp. 1972, 14:767-774.
17. Hanlon T.E., Kay Y., Agallianos D., Berman A., Bethon C., Kolber F., Kurland A.A. Combined drug treatment of newly hospitalized, acutely ill psychiatric patients. Dis. Nerv. Syst. 1969, 30:104-116.
18. Hanlon T.E., Ota K.Y., Kurland A.A. Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine. Dis. Nerv. Syst. 1970, 31:171-177.
19. Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F., Möller, H.J., WFSBP task force on treatment guidelines for schizophrenia, 2012. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part1: update on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry 13, 318-378.
20. Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F., Möller, H.J., WFSBP task force on treatment guidelines for schizophrenia, 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part2: update on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World.J. Biol. Psychiatry 14, 2-44.
21. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 2011, The Cochrane Collaboration, [updated March 2011].
22. Holden J.M.C., Itil T.M., Keskiner A., Fink M. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Compr. Psychiatry 1968, 9:633-643.
23. Kay S.R., Fiszbein A. The positive and negative symptom scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-275.
24. Kurland A.A., Bethon G.D., Michaux M.H., Agallianos D.D. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings. J. New Drugs 1966, 6:80-95.
25. Kutcher S., Williamson P., MacKenzie S., Marton P., Ehrlich M. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 1989, 9:403-406.
26. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. American psychiatric association, steering committee on practice guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161:1-56.
27. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31:2318-2325.
28. Lingjaerde O., Engstrand E., Ellingsen P., Robak O.H. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients - a double-blind clinical trial. Curr. Ther. Res. Clin. Exp. 1979, 26:505-514.
29. Lingjaerde O. Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study. Acta Psychiatr. Scand. 1982, 65:339-354.
30. Ma C. The control study of injection of clonazepam into tinggong for auditory hallucination of schizophrenia. J. Clin. Psychosom. Dis. 2006, 12:338-339.
31. Marneros A. Anxiolytische Zusatzbehandlung bei den affektbetonten Schizophrenien. Ein Doppelblindversuch. Therapiewoche 1979, 29:7533-7538.
32. Morphy M. A double-blind comparison of alprazolam and placebo in the treatment of anxious schizophrenic outpatients. Curr. Ther. Res. Clin. Exp. 1986, 40:551-560.
33. National Institute for Health and Clinical Excellence (NICE), 2009. Schizophrenia - core interventions in the treatment and management of schizophrenia in adults in primary and secondary care, [update 2009].
34. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:790-812.
35. Pickar D., Vinik J., Bartko J.J. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One 2008, 3:e3150.
36. Pujalte D., Battai T., Hue B., Alric R., Pouget R., Blayac J.P., Petit P. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin. Neuropharmacol. 1994, 17:236-242.
37. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans affairs cooperative study group on clozapine in refractory schizophrenia. N. Engl. J. Med. 1997, 337:809-815.
38. Rummel C., Kissling W., Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr. Res. 2005, 80:85-97.
39. Sommer I.E., Begemann M.J., Temmerman A., Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr. Bull. 2012, 38:1003-1011.
40. Stevens A., Stevens I., Mahal A., Gaertner H.J. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Pharmacopsychiatry 1992, 25:273-277.
41. Suzuki T., Remington G., Mulsant B.H., Rajji T.K., Uchida H., Graff-Guerrero A., Mamo D.C. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr. Res. 2011, 133:54-62.
42. Tiihonen J., Suokas J.T., Suvisaari J.M., Haukka J., Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch. Gen. Psychiatry 2012, 69:476-483.
43. The Cochrance Collaboration, 2011. Software Review Manager (RevMan), Version 5.1.2.
44. TREC Collaborative Group Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. Br. Med. J. 2003, 327:708-713.
45. Wang G., Ji R., Pei G. The control study of injection of clonazepam into tD́ingkung for refractory auditory hallucination of schizophrenics. J. Clin. Psychosom. Dis. 2000, 6:143-144.
46. Wang X., Wang X., Zhou H. An efficacy study of risperidone combined with clonazepam injection in the treatment of paranoid schizophrenia. J. Clin. Psychol. Med. 2003, 13:217-218.
47. Wilson S.J., Nutt D.J., Alford C., Argyropoulos S.V., Baldwin D.S., Bateson A.N., Britton T.C., Crowe C., Dijk D.J., Espie C.A., Gringras P., Hajak G., Idzikowski C., Krystal A.D., Nash J.R., Selsick H., Sharpley A.L., Wade A,G. British association for psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J. Psychopharmacol. 2010, 24:1577-1601.
48. Wolkowitz O.M., Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am. J. Psychiatry 1991, 148:714-726.
49. Xuan G.H., Chu Y. Clinical observation on the effect of risperidone combined with BZD on schizophrenia. China Trop. Med. 2007, 7:244.